Sign In
Buy ALDX
$1.86
+0.220 (+13.41%)
At Close: Jun 03, 2026
Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
07:01am, Wednesday, 06'th Aug 2025
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the European Medicines Agency (EMA) has granted Orphan Designation for ADX-2191 (methotrexat
Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease
07:00am, Thursday, 17'th Jul 2025
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats
10:05am, Wednesday, 16'th Jul 2025
Innovation is at its peak in the Zacks Medical-Drugs industry. CPRX, ZVRA, TBPH, ALDX and LRMR may prove to be good additions to one's portfolio.
Aldeyra Therapeutics (ALDX) Upgraded to Strong Buy: What Does It Mean for the Stock?
01:01pm, Tuesday, 15'th Jul 2025
Aldeyra Therapeutics (ALDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Aldeyra Therapeutics: Pivotal FDA Decision After Reproxalap's Chamber Data
09:23pm, Wednesday, 02'nd Jul 2025
Aldeyra Therapeutics' Reproxalap is now on its third NDA, which was filed in June 2025. It supposedly fixes prior trial flaws. ALDX believes a potential FDA acceptance could set a PDUFA date for Decem
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced receipt of a Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administrat
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease
07:00am, Tuesday, 17'th Jun 2025
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune‑me
Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference
07:01am, Thursday, 29'th May 2025
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
09:00am, Friday, 16'th May 2025
NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ:ALDX). Such investo
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
09:00am, Wednesday, 14'th May 2025
NEW YORK CITY, NY / ACCESS Newswire / May 14, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ:ALDX). Such investo
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra Therapeutics, Inc. – ALDX
01:22pm, Tuesday, 13'th May 2025
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ: ALDX). Such investor
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
05:46pm, Monday, 12'th May 2025
NEW YORK , May 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX). Such investors are ad
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
08:00am, Saturday, 10'th May 2025
NEW YORK CITY, NY / ACCESS Newswire / May 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ:ALDX). Such investo
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
08:00am, Thursday, 08'th May 2025
NEW YORK CITY, NY / ACCESS Newswire / May 8, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ:ALDX). Such investor
